Details of the Drug Combinations

General Information of This Drug (ID: DMRHGI9)

Drug Name
Cisplatin   DMRHGI9
Synonyms
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Anterior urethra cancer N.A. Approved [1]
Carcinoma 2A00-2F9Z Approved [1]
Central nervous system neoplasm N.A. Approved [1]
Epithelial ovarian cancer 2B5D Approved [1]
Epithelioid mesothelioma 2F10 Approved [1]
Esophageal squamous cell carcinoma 2E60.1 Approved [1]
Extragonadal germ cell tumor N.A. Approved [1]
Gastric intestinal type adenocarcinoma N.A. Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Posterior urethra cancer N.A. Approved [1]
Primary peritoneal carcinoma N.A. Approved [1]
Primitive neuroectodermal tumor N.A. Approved [1]
Sarcomatoid mesothelioma N.A. Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular germ cell tumor N.A. Approved [1]
Urinary bladder neoplasm N.A. Approved [1]
Osteosarcoma 2B51 Phase 2 [3]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

398 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Cisplatin DCACZBO 10-hydroxycamptothecin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
10-hydroxycamptothecin + Cisplatin DCVUD6J 10-hydroxycamptothecin Anaplastic large cell lymphoma (Cell Line: SR) [4]
10-hydroxycamptothecin + Cisplatin DC6L21O 10-hydroxycamptothecin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
10-hydroxycamptothecin + Cisplatin DCHKH7A 10-hydroxycamptothecin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
10-hydroxycamptothecin + Cisplatin DC2S90X 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
10-hydroxycamptothecin + Cisplatin DC7OF5M 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: COLO 205) [5]
10-hydroxycamptothecin + Cisplatin DCXC12P 10-hydroxycamptothecin Malignant melanoma (Cell Line: LOX IMVI) [6]
10-hydroxycamptothecin + Cisplatin DC4I50L 10-hydroxycamptothecin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
ABIRATERONE + Cisplatin DCHBVZQ ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
ABIRATERONE + Cisplatin DC7KNOM ABIRATERONE Astrocytoma (Cell Line: SNB-19) [4]
ABIRATERONE + Cisplatin DCJBSJW ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [4]
ABIRATERONE + Cisplatin DCNMKCN ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [4]
ABIRATERONE + Cisplatin DCVSL1A ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [5]
ABIRATERONE + Cisplatin DCRFIB7 ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [6]
ABIRATERONE + Cisplatin DCZGJMR ABIRATERONE Malignant melanoma (Cell Line: UACC62) [6]
ABIRATERONE + Cisplatin DCH5HNF ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [6]
ABIRATERONE + Cisplatin DC9LCDA ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Aminolevulinic Acid Hydrochloride + Cisplatin DCQTV9L Aminolevulinic Acid Hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Aminolevulinic Acid Hydrochloride + Cisplatin DCHI9QC Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Aminolevulinic Acid Hydrochloride + Cisplatin DCL2CQ9 Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [4]
Aminolevulinic Acid Hydrochloride + Cisplatin DCAS2AV Aminolevulinic Acid Hydrochloride Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Aminolevulinic Acid Hydrochloride + Cisplatin DCA6KKK Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: HCT116) [6]
Anastrozole + Cisplatin DCBAIG1 Anastrozole Adenocarcinoma (Cell Line: DU-145) [4]
Anastrozole + Cisplatin DCG41Y7 Anastrozole Adenocarcinoma (Cell Line: A549) [4]
Anastrozole + Cisplatin DCZOZWD Anastrozole Adenocarcinoma (Cell Line: HCT-15) [4]
Anastrozole + Cisplatin DCRXAEX Anastrozole Adenocarcinoma (Cell Line: HT29) [4]
Anastrozole + Cisplatin DCTLDDS Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Anastrozole + Cisplatin DC0554K Anastrozole Amelanotic melanoma (Cell Line: M14) [4]
Anastrozole + Cisplatin DC07872 Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Anastrozole + Cisplatin DCSWBNP Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Anastrozole + Cisplatin DCXERDL Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Anastrozole + Cisplatin DC6DE0Z Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Anastrozole + Cisplatin DCQLHAN Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Anastrozole + Cisplatin DCA7CID Anastrozole Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Anastrozole + Cisplatin DC5C7XA Anastrozole Lung adenocarcinoma (Cell Line: HOP-62) [4]
Anastrozole + Cisplatin DCXDNMD Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Anastrozole + Cisplatin DCB3TOC Anastrozole Malignant melanoma (Cell Line: UACC62) [4]
Anastrozole + Cisplatin DC7ZEQN Anastrozole Melanoma (Cell Line: MALME-3M) [4]
Anastrozole + Cisplatin DCNQ9UY Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Anastrozole + Cisplatin DC3PWCD Anastrozole Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Anastrozole + Cisplatin DCDPH1B Anastrozole Carcinoma (Cell Line: MCF7) [5]
Anastrozole + Cisplatin DCFTDY3 Anastrozole Invasive ductal carcinoma (Cell Line: T-47D) [5]
Anastrozole + Cisplatin DC9CYNU Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [5]
Anastrozole + Cisplatin DCKA27G Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Arfolitixorin + Cisplatin DC894W7 Arfolitixorin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Azacitidine + Cisplatin DC3479T Azacitidine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Cisplatin DCF06YY Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Cisplatin DCT6SNU Azacitidine Astrocytoma (Cell Line: U251) [4]
Azacitidine + Cisplatin DCOSOQJ Azacitidine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Cisplatin DCCTTI5 Azacitidine Lung adenocarcinoma (Cell Line: EKVX) [4]
Azacitidine + Cisplatin DCFISDU Azacitidine Malignant melanoma (Cell Line: LOX IMVI) [4]
Azacitidine + Cisplatin DCU09N8 Azacitidine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Azacitidine + Cisplatin DCSB7OF Azacitidine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Bendamustine hydrochloride + Cisplatin DC56382 Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [4]
Bendamustine hydrochloride + Cisplatin DC1XR12 Bendamustine hydrochloride Malignant melanoma (Cell Line: LOX IMVI) [6]
Bendamustine hydrochloride + Cisplatin DCY5UAQ Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [6]
Bendamustine hydrochloride + Cisplatin DC97QKM Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [6]
Bleomycin + Cisplatin DCF17PK Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Bleomycin + Cisplatin DC58M1G Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Bleomycin + Cisplatin DC91IUL Bleomycin Astrocytoma (Cell Line: U251) [4]
Bleomycin + Cisplatin DC60D5U Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Bleomycin + Cisplatin DC2F94E Bleomycin Adenocarcinoma (Cell Line: OVCAR3) [6]
Bleomycin + Cisplatin DCIY604 Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [6]
Bleomycin + Cisplatin DCYKN2Z Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Bortezomib + Cisplatin DC53QUT Bortezomib Adenocarcinoma (Cell Line: A549) [4]
Bortezomib + Cisplatin DCDAUYD Bortezomib Glioma (Cell Line: SF-539) [4]
Bortezomib + Cisplatin DCL8YUB Bortezomib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Bortezomib + Cisplatin DCGHCWD Bortezomib Melanoma (Cell Line: MALME-3M) [4]
Bortezomib + Cisplatin DCFORLO Bortezomib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Bortezomib + Cisplatin DCD9KC6 Bortezomib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Busulfan + Cisplatin DCO26WC Busulfan Adenocarcinoma (Cell Line: DU-145) [4]
Busulfan + Cisplatin DC4YCWB Busulfan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Busulfan + Cisplatin DCW3NTJ Busulfan Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Cabazitaxel + Cisplatin DCLATA3 Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Cabazitaxel + Cisplatin DCEBTO2 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Chlorambucil + Cisplatin DC7IMEH Chlorambucil Anaplastic large cell lymphoma (Cell Line: SR) [4]
Chlorambucil + Cisplatin DCLEC9I Chlorambucil Malignant melanoma (Cell Line: LOX IMVI) [4]
Chlorambucil + Cisplatin DCT7ATY Chlorambucil Melanoma (Cell Line: SK-MEL-2) [4]
Cisplatin + Arsenic trioxide DCML61U Arsenic trioxide Adenocarcinoma (Cell Line: OVCAR3) [4]
Cisplatin + Arsenic trioxide DCKFP9B Arsenic trioxide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Cisplatin + Arsenic trioxide DC99Z6C Arsenic trioxide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Cisplatin + Arsenic trioxide DCSF15H Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Cisplatin + Arsenic trioxide DCOX0WL Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Cisplatin + Arsenic trioxide DCSPGI8 Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Cisplatin + Arsenic trioxide DCZ3R2L Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Cisplatin + Arsenic trioxide DCWEUKQ Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Cisplatin + Arsenic trioxide DCPE2HU Arsenic trioxide Lung adenocarcinoma (Cell Line: EKVX) [4]
Cisplatin + Arsenic trioxide DCL94B3 Arsenic trioxide Malignant melanoma (Cell Line: LOX IMVI) [4]
Cisplatin + Arsenic trioxide DCFBUUW Arsenic trioxide Malignant melanoma (Cell Line: UACC62) [4]
Cisplatin + Arsenic trioxide DCGN0H8 Arsenic trioxide Melanoma (Cell Line: MALME-3M) [4]
Cisplatin + Arsenic trioxide DCO0QPY Arsenic trioxide Melanoma (Cell Line: SK-MEL-2) [4]
Cisplatin + Arsenic trioxide DCLUHQW Arsenic trioxide Renal cell carcinoma (Cell Line: UO-31) [4]
Cisplatin + Arsenic trioxide DC4MFLB Arsenic trioxide Invasive ductal carcinoma (Cell Line: BT-549) [5]
Cisplatin + Arsenic trioxide DCJ748Z Arsenic trioxide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Crizotinib + Cisplatin DCS7LCF Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Crizotinib + Cisplatin DC8G4T9 Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dacarbazine + Cisplatin DCDAK6H Dacarbazine Adenocarcinoma (Cell Line: HCT-15) [4]
Dacarbazine + Cisplatin DCW41HM Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Dacarbazine + Cisplatin DC3LWL4 Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Dacarbazine + Cisplatin DC0HJRJ Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Dacarbazine + Cisplatin DCZ2GMY Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Dactinomycin + Cisplatin DCTJVTE Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dactinomycin + Cisplatin DCJCLLZ Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [6]
Dactinomycin + Cisplatin DC6COCW Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Dactinomycin + Cisplatin DCLE5E1 Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Dactinomycin + Cisplatin DCHQ0OL Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Dasatinib + Cisplatin DCJX7ZN Dasatinib Adenocarcinoma (Cell Line: A549) [4]
Dasatinib + Cisplatin DCLKOS0 Dasatinib Amelanotic melanoma (Cell Line: M14) [4]
Dasatinib + Cisplatin DCQH03G Dasatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Dasatinib + Cisplatin DCJ0RJA Dasatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Dasatinib + Cisplatin DCTBFUK Dasatinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Dasatinib + Cisplatin DCSJS6R Dasatinib Melanoma (Cell Line: MALME-3M) [4]
Dexrazoxane + Cisplatin DCV5YMA Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dexrazoxane + Cisplatin DC0XDXE Dexrazoxane Glioblastoma (Cell Line: SNB-75) [4]
Dexrazoxane + Cisplatin DCSAX9E Dexrazoxane Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Dexrazoxane + Cisplatin DC62I8L Dexrazoxane Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dexrazoxane + Cisplatin DC3Q82R Dexrazoxane Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Dexrazoxane + Cisplatin DCXNC45 Dexrazoxane Adenocarcinoma (Cell Line: SW-620) [6]
Dexrazoxane + Cisplatin DC6HKBE Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [6]
Dexrazoxane + Cisplatin DCA6943 Dexrazoxane Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Dexrazoxane + Cisplatin DC60ALG Dexrazoxane Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Dexrazoxane + Cisplatin DCGMVCJ Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Dexrazoxane + Cisplatin DC2IRLA Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Dexrazoxane + Cisplatin DCG7WT1 Dexrazoxane Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Dexrazoxane + Cisplatin DCZR9EX Dexrazoxane Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Digitoxin + Cisplatin DCRA1IM Digitoxin Adenocarcinoma (Cell Line: A549) [4]
Digitoxin + Cisplatin DCY0CSD Digitoxin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Digitoxin + Cisplatin DC8CTGO Digitoxin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Digitoxin + Cisplatin DCQM69E Digitoxin Astrocytoma (Cell Line: U251) [4]
Digitoxin + Cisplatin DCPRJIV Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Digitoxin + Cisplatin DCDVGRF Digitoxin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Digitoxin + Cisplatin DC3YJT5 Digitoxin Lung adenocarcinoma (Cell Line: EKVX) [4]
Digitoxin + Cisplatin DCHJ5RQ Digitoxin Malignant melanoma (Cell Line: LOX IMVI) [4]
Digitoxin + Cisplatin DC2Y0J3 Digitoxin Melanoma (Cell Line: MALME-3M) [4]
Digitoxin + Cisplatin DCSVKDC Digitoxin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Digitoxin + Cisplatin DCXB7SO Digitoxin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Digitoxin + Cisplatin DCX7KLZ Digitoxin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Docetaxel + Cisplatin DCQR8O0 Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Docetaxel + Cisplatin DCTE5B8 Docetaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Docetaxel + Cisplatin DCRPUOU Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Docetaxel + Cisplatin DCGH4JH Docetaxel Malignant melanoma (Cell Line: UACC62) [4]
Docetaxel + Cisplatin DCI5CAO Docetaxel Carcinoma (Cell Line: RXF 393) [5]
Epirubicin + Cisplatin DCIDHLH Epirubicin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Epirubicin + Cisplatin DC93PE3 Epirubicin Astrocytoma (Cell Line: SNB-19) [4]
Epirubicin + Cisplatin DCR5054 Epirubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Epirubicin + Cisplatin DCVU9EX Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Epirubicin + Cisplatin DCUBM19 Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Epirubicin + Cisplatin DCSKAYD Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Epirubicin + Cisplatin DCLBAZL Epirubicin Renal cell carcinoma (Cell Line: UO-31) [4]
Epirubicin + Cisplatin DCD3IYU Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Epirubicin + Cisplatin DC9Z25M Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Epirubicin + Cisplatin DC9ED2P Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Epirubicin + Cisplatin DCSORVJ Epirubicin Adenocarcinoma (Cell Line: OVCAR3) [6]
Epirubicin + Cisplatin DCIJF0J Epirubicin Adenocarcinoma (Cell Line: HCT-15) [6]
Epirubicin + Cisplatin DC2NO9N Epirubicin Adenocarcinoma (Cell Line: HT29) [6]
Epirubicin + Cisplatin DCGYVGD Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Epirubicin + Cisplatin DC9KFLX Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Epirubicin + Cisplatin DCFQ39F Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Epirubicin + Cisplatin DCC0GHK Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [6]
Epirubicin + Cisplatin DCUVD34 Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [6]
Epirubicin + Cisplatin DCJB4OP Epirubicin Melanoma (Cell Line: UACC-257) [6]
Epirubicin + Cisplatin DCGQUFM Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Epirubicin + Cisplatin DC73IMB Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Epirubicin + Cisplatin DCZBKF3 Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
ER819762 + Cisplatin DCWKEYH ER819762 Astrocytoma (Cell Line: U251) [4]
ER819762 + Cisplatin DCR0PVN ER819762 Glioma (Cell Line: SF-268) [4]
ER819762 + Cisplatin DC2CF5O ER819762 Adenocarcinoma (Cell Line: OVCAR3) [6]
ER819762 + Cisplatin DCO3EG5 ER819762 Melanoma (Cell Line: SK-MEL-2) [6]
Estramustine + Cisplatin DCSYN3Z Estramustine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Estramustine + Cisplatin DCY15SS Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Estramustine + Cisplatin DCTPY3Q Estramustine Carcinoma (Cell Line: RXF 393) [5]
Estramustine + Cisplatin DCIFQNM Estramustine Adenocarcinoma (Cell Line: HCT116) [6]
Fludarabine + Cisplatin DCBVJAC Fludarabine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Fludarabine + Cisplatin DC9Y22H Fludarabine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Fludarabine + Cisplatin DCK4VG6 Fludarabine Astrocytoma (Cell Line: U251) [4]
Fludarabine + Cisplatin DC8CDI3 Fludarabine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Fludarabine + Cisplatin DCOW8XH Fludarabine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Fludarabine + Cisplatin DCE4J80 Fludarabine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Fludarabine + Cisplatin DCO6N80 Fludarabine Amelanotic melanoma (Cell Line: M14) [6]
Fludarabine + Cisplatin DCWURV2 Fludarabine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Fulvestrant + Cisplatin DCO3GIX Fulvestrant Melanoma (Cell Line: SK-MEL-2) [4]
Gefitinib + Cisplatin DC6SWKQ Gefitinib Adenocarcinoma (Cell Line: HT29) [4]
Gefitinib + Cisplatin DCEXNCP Gefitinib Adenocarcinoma (Cell Line: SW-620) [4]
Gefitinib + Cisplatin DCK2LBG Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Gefitinib + Cisplatin DC55LDC Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Gefitinib + Cisplatin DCVBLTH Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Idarubicin + Cisplatin DCJL8PZ Idarubicin Malignant melanoma (Cell Line: LOX IMVI) [6]
Imatinib + Cisplatin DCVCKAO Imatinib Glioma (Cell Line: SF-539) [4]
Indazole derivative 5 + Cisplatin DCDHAU1 Indazole derivative 5 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Indazole derivative 5 + Cisplatin DC0FGQR Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [5]
Indazole derivative 5 + Cisplatin DCT2WNG Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Indazole derivative 5 + Cisplatin DCHDXSC Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [6]
Indazole derivative 5 + Cisplatin DCYY0P4 Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Indazole derivative 5 + Cisplatin DCICGG6 Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [6]
Isoniazid + Cisplatin DC1OIGC Isoniazid Astrocytoma (Cell Line: U251) [4]
Isoniazid + Cisplatin DCPXTEF Isoniazid Chronic myelogenous leukemia (Cell Line: K-562) [4]
Isoniazid + Cisplatin DCB3UXI Isoniazid High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Isoniazid + Cisplatin DCTKL8S Isoniazid Melanoma (Cell Line: SK-MEL-2) [4]
Ixabepilone + Cisplatin DCOJPIZ Ixabepilone Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lapatinib + Cisplatin DCGF0M5 Lapatinib Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Cisplatin DCLF64X Lenalidomide Glioma (Cell Line: SF-268) [4]
Lenalidomide + Cisplatin DCKA8CR Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Cisplatin DC46A7B Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Cisplatin DC1RFGE Lenalidomide Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Cisplatin DCWDN1W Lenalidomide Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Cisplatin DC2QVZR Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Cisplatin DCBGT6J Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Cisplatin DC5DDH0 Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Lenalidomide + Cisplatin DC5XPAL Lenalidomide Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Cisplatin DCSMMVR Lenalidomide Melanoma (Cell Line: SK-MEL-2) [6]
Letrozole + Cisplatin DC5DFZD Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Letrozole + Cisplatin DCTZBVT Letrozole Invasive ductal carcinoma (Cell Line: HS 578T) [5]
LIAROZOLE + Cisplatin DC6R17R LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
LIAROZOLE + Cisplatin DCUYQVU LIAROZOLE Anaplastic large cell lymphoma (Cell Line: SR) [4]
LIAROZOLE + Cisplatin DCVQXR8 LIAROZOLE Melanoma (Cell Line: UACC-257) [6]
Mechlorethamine + Cisplatin DCNRX3R Mechlorethamine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Mechlorethamine + Cisplatin DCI233K Mechlorethamine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Mechlorethamine + Cisplatin DCKQCO6 Mechlorethamine Adenocarcinoma (Cell Line: HCC-2998) [6]
Mechlorethamine + Cisplatin DCF0E37 Mechlorethamine Amelanotic melanoma (Cell Line: M14) [6]
Mechlorethamine + Cisplatin DC91RCI Mechlorethamine Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Mechlorethamine + Cisplatin DCM77EL Mechlorethamine Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Mechlorethamine + Cisplatin DCSLBST Mechlorethamine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Mepacrine + Cisplatin DCN1SHY Mepacrine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Mepacrine + Cisplatin DCVHQXY Mepacrine Clear cell renal cell carcinoma (Cell Line: A498) [4]
Mepacrine + Cisplatin DC0IASI Mepacrine Adenocarcinoma (Cell Line: DU-145) [6]
Mepacrine + Cisplatin DCKPKSB Mepacrine Melanoma (Cell Line: UACC-257) [6]
Mercaptopurine + Cisplatin DCN55QN Mercaptopurine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Mercaptopurine + Cisplatin DC884RG Mercaptopurine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Mercaptopurine + Cisplatin DCGD0QL Mercaptopurine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Mercaptopurine + Cisplatin DCEHB8H Mercaptopurine Adenocarcinoma (Cell Line: DU-145) [6]
Mercaptopurine + Cisplatin DCPDKUE Mercaptopurine Adenocarcinoma (Cell Line: HCT-15) [6]
Mercaptopurine + Cisplatin DCULB34 Mercaptopurine Adenocarcinoma (Cell Line: HCT116) [6]
Mercaptopurine + Cisplatin DCG4EKR Mercaptopurine Lung adenocarcinoma (Cell Line: EKVX) [6]
Mercaptopurine + Cisplatin DCIDVYV Mercaptopurine Malignant melanoma (Cell Line: LOX IMVI) [6]
Mitomycin + Cisplatin DCU2RBW Mitomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Mitomycin + Cisplatin DCLBNFX Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Mitomycin + Cisplatin DCG8LIY Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Mitomycin + Cisplatin DCKFS3O Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Mitomycin + Cisplatin DCNQNUW Mitomycin Melanoma (Cell Line: MALME-3M) [6]
Mitomycin + Cisplatin DC0BT85 Mitomycin Melanoma (Cell Line: SK-MEL-2) [6]
Nilotinib + Cisplatin DC5BQ18 Nilotinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Nilotinib + Cisplatin DC0HR2Z Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Nilotinib + Cisplatin DCJWEBA Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Nilotinib + Cisplatin DCBLWO0 Nilotinib Prostate carcinoma (Cell Line: PC-3) [6]
Pentostatin + Cisplatin DCEQ9HQ Pentostatin Adenocarcinoma (Cell Line: A549) [4]
Pentostatin + Cisplatin DCC9IBR Pentostatin Adenocarcinoma (Cell Line: HT29) [4]
Pentostatin + Cisplatin DCOE8ZF Pentostatin Adenocarcinoma (Cell Line: HCC-2998) [4]
Pentostatin + Cisplatin DCUNN67 Pentostatin Glioma (Cell Line: SF-539) [4]
Pentostatin + Cisplatin DCC2AUQ Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Pentostatin + Cisplatin DCE2DN8 Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Pentostatin + Cisplatin DC27VIW Pentostatin Melanoma (Cell Line: SK-MEL-2) [4]
Pentostatin + Cisplatin DCWRDOQ Pentostatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Pentostatin + Cisplatin DCT8V8M Pentostatin Carcinoma (Cell Line: RXF 393) [5]
Picoplatin + Cisplatin DCUOFVP Picoplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Picoplatin + Cisplatin DC50IM8 Picoplatin Glioblastoma (Cell Line: SNB-75) [4]
Picoplatin + Cisplatin DC416PV Picoplatin Adenocarcinoma (Cell Line: A549) [6]
Picoplatin + Cisplatin DC6UNMO Picoplatin Amelanotic melanoma (Cell Line: M14) [6]
Picoplatin + Cisplatin DC91C3A Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Picoplatin + Cisplatin DCI0TJQ Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Picoplatin + Cisplatin DCBGGAO Picoplatin Melanoma (Cell Line: SK-MEL-2) [6]
Picoplatin + Cisplatin DCJ9C67 Picoplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Picoplatin + Cisplatin DC0NJI9 Picoplatin Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Picoplatin + Cisplatin DCSIK94 Picoplatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Cisplatin DC1MZN6 Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Plicamycin + Cisplatin DCODKCZ Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Cisplatin DCA6SSH Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Plicamycin + Cisplatin DCD9BOZ Plicamycin Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Cisplatin DCODEWG Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [6]
PMID28460551-Compound-2 + Cisplatin DCIDRCG PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
PMID28460551-Compound-2 + Cisplatin DC372Q5 PMID28460551-Compound-2 Astrocytoma (Cell Line: U251) [4]
PMID28460551-Compound-2 + Cisplatin DCYY36L PMID28460551-Compound-2 Astrocytoma (Cell Line: SNB-19) [4]
PMID28460551-Compound-2 + Cisplatin DCAYTFG PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
PMID28460551-Compound-2 + Cisplatin DC3S6YS PMID28460551-Compound-2 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
PMID28460551-Compound-2 + Cisplatin DCG2GX4 PMID28460551-Compound-2 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
PMID28460551-Compound-2 + Cisplatin DCTOWIS PMID28460551-Compound-2 Renal cell carcinoma (Cell Line: SN12C) [4]
PMID28460551-Compound-2 + Cisplatin DCSVFXU PMID28460551-Compound-2 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
PMID28460551-Compound-2 + Cisplatin DCAQKDM PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [5]
PMID28460551-Compound-2 + Cisplatin DCAEQ9M PMID28460551-Compound-2 Carcinoma (Cell Line: MCF7) [5]
PMID28460551-Compound-2 + Cisplatin DC1F4TN PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
PMID28460551-Compound-2 + Cisplatin DC98IRH PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [6]
PMID28460551-Compound-2 + Cisplatin DCSW50N PMID28460551-Compound-2 Adenocarcinoma (Cell Line: A549) [6]
PMID28460551-Compound-2 + Cisplatin DCF5HCZ PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
PMID28460551-Compound-2 + Cisplatin DCOALNC PMID28460551-Compound-2 Malignant melanoma (Cell Line: LOX IMVI) [6]
PMID28460551-Compound-2 + Cisplatin DCQ2VH8 PMID28460551-Compound-2 Melanoma (Cell Line: SK-MEL-2) [6]
PMID28460551-Compound-2 + Cisplatin DC1D022 PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
PMID28460551-Compound-2 + Cisplatin DCSLOTU PMID28460551-Compound-2 Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Pralatrexate + Cisplatin DC2DW1L Pralatrexate Glioma (Cell Line: SF-268) [4]
Pralatrexate + Cisplatin DCTBTZ5 Pralatrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Raloxifene + Cisplatin DCCY9RH Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Raloxifene + Cisplatin DC1787Y Raloxifene Astrocytoma (Cell Line: SNB-19) [4]
Raloxifene + Cisplatin DCE7HR8 Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Raloxifene + Cisplatin DCSR8TQ Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Raloxifene + Cisplatin DC39PV6 Raloxifene Adenocarcinoma (Cell Line: SW-620) [6]
Raloxifene + Cisplatin DCYFZR8 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Raloxifene + Cisplatin DCTDU7A Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Raloxifene + Cisplatin DC342XH Raloxifene Melanoma (Cell Line: MALME-3M) [6]
Raloxifene + Cisplatin DCR6UDU Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Romidepsin + Cisplatin DCLC0R6 Romidepsin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Romidepsin + Cisplatin DC38H9L Romidepsin Glioma (Cell Line: SF-268) [4]
Romidepsin + Cisplatin DC0L3QA Romidepsin Glioma (Cell Line: SF-539) [4]
Romidepsin + Cisplatin DCBUX1O Romidepsin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Romidepsin + Cisplatin DCJ5X3Z Romidepsin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Romidepsin + Cisplatin DC3B8RF Romidepsin Adenocarcinoma (Cell Line: A549) [6]
Romidepsin + Cisplatin DCEO3C7 Romidepsin Adenocarcinoma (Cell Line: NCIH23) [6]
Romidepsin + Cisplatin DCJ5XCQ Romidepsin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Romidepsin + Cisplatin DCMTM53 Romidepsin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Romidepsin + Cisplatin DCTFIT1 Romidepsin Melanoma (Cell Line: MALME-3M) [6]
Ruxolitinib + Cisplatin DC219XZ Ruxolitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Ruxolitinib + Cisplatin DC3QMRX Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ruxolitinib + Cisplatin DCORE6X Ruxolitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Ruxolitinib + Cisplatin DCON1DE Ruxolitinib Astrocytoma (Cell Line: SNB-19) [4]
Ruxolitinib + Cisplatin DCNAKGS Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Ruxolitinib + Cisplatin DC6NGA2 Ruxolitinib Glioma (Cell Line: SF-268) [4]
Ruxolitinib + Cisplatin DC6GRZ2 Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Ruxolitinib + Cisplatin DC2LP6X Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Ruxolitinib + Cisplatin DC0PL2Z Ruxolitinib Carcinoma (Cell Line: MCF7) [5]
Ruxolitinib + Cisplatin DCDLY8J Ruxolitinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Ruxolitinib + Cisplatin DC0R1FD Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Ruxolitinib + Cisplatin DCCTN3M Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Ruxolitinib + Cisplatin DCJ7VG5 Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Ruxolitinib + Cisplatin DCXFBIT Ruxolitinib Adenocarcinoma (Cell Line: HT29) [6]
Ruxolitinib + Cisplatin DCXZOX1 Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Ruxolitinib + Cisplatin DCOOYLR Ruxolitinib Melanoma (Cell Line: MALME-3M) [6]
SCH 727965 + Cisplatin DC1R0WB SCH 727965 Adenocarcinoma (Cell Line: HCC-2998) [6]
Sirolimus + Cisplatin DC8ABAP Sirolimus Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Sirolimus + Cisplatin DCAL12A Sirolimus Glioma (Cell Line: SF-539) [4]
Sirolimus + Cisplatin DC102KS Sirolimus Adenocarcinoma (Cell Line: A549) [6]
Sirolimus + Cisplatin DCU4UY7 Sirolimus Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Sirolimus + Cisplatin DCOUWAR Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [6]
SY-1425 + Cisplatin DC6TIZ8 SY-1425 Lung adenocarcinoma (Cell Line: EKVX) [6]
Taxol + Cisplatin DC45XD8 Taxol Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Taxol + Cisplatin DCAT885 Taxol Adenocarcinoma (Cell Line: A549) [6]
TEM + Cisplatin DC4N67B TEM Glioma (Cell Line: SF-539) [4]
Terameprocol + Cisplatin DCIH05X Terameprocol Adenocarcinoma (Cell Line: HCT116) [6]
Thioguanine + Cisplatin DCEDMIW Thioguanine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Topetecan + Cisplatin DCR5YGT Topetecan Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Topetecan + Cisplatin DC6D9B6 Topetecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Topetecan + Cisplatin DC2CHXU Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [4]
Topetecan + Cisplatin DCNGB80 Topetecan Astrocytoma (Cell Line: SNB-19) [4]
Topetecan + Cisplatin DC22E3C Topetecan Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Topetecan + Cisplatin DC5FONV Topetecan Carcinoma (Cell Line: RXF 393) [5]
Topetecan + Cisplatin DCZHIAX Topetecan Colon adenocarcinoma (Cell Line: COLO 205) [5]
Topetecan + Cisplatin DCZD7EF Topetecan Invasive ductal carcinoma (Cell Line: T-47D) [5]
Topetecan + Cisplatin DCV6J8K Topetecan Adenocarcinoma (Cell Line: DU-145) [6]
Topetecan + Cisplatin DCDUI9A Topetecan Adenocarcinoma (Cell Line: OVCAR3) [6]
Topetecan + Cisplatin DCS0M4E Topetecan Malignant melanoma (Cell Line: LOX IMVI) [6]
Topotecan + Cisplatin DCM7LBD Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Topotecan + Cisplatin DCUIX3F Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Topotecan + Cisplatin DC1G946 Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Topotecan + Cisplatin DC86GDT Topotecan Amelanotic melanoma (Cell Line: M14) [6]
Topotecan + Cisplatin DCV7E7B Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Topotecan + Cisplatin DCJMFL3 Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Topotecan + Cisplatin DCC8AX9 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Topotecan + Cisplatin DC23SIZ Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Topotecan + Cisplatin DCEKXYK Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Triapine + Cisplatin DCBMN8X Triapine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Trifluridine + Cisplatin DCS7Q57 Trifluridine Astrocytoma (Cell Line: U251) [4]
Trifluridine + Cisplatin DCPNE5D Trifluridine Adenocarcinoma (Cell Line: NCIH23) [6]
Valrubicin + Cisplatin DCO0O2Y Valrubicin Astrocytoma (Cell Line: SNB-19) [4]
Valrubicin + Cisplatin DCKM6M8 Valrubicin Adenocarcinoma (Cell Line: DU-145) [6]
Valrubicin + Cisplatin DC2RL3P Valrubicin Adenocarcinoma (Cell Line: A549) [6]
Valrubicin + Cisplatin DC2GPF1 Valrubicin Adenocarcinoma (Cell Line: NCIH23) [6]
Valrubicin + Cisplatin DCCUGVG Valrubicin Adenocarcinoma (Cell Line: HT29) [6]
Valrubicin + Cisplatin DCPVUYQ Valrubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Valrubicin + Cisplatin DCNTJ4P Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Vandetanib + Cisplatin DCYVH5W Vandetanib Colon carcinoma (Cell Line: KM12) [5]
Vandetanib + Cisplatin DCTVBD4 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vandetanib + Cisplatin DCAYAEY Vandetanib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vandetanib + Cisplatin DCGEGCV Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vandetanib + Cisplatin DCB2BK0 Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vandetanib + Cisplatin DCCFDTG Vandetanib Melanoma (Cell Line: SK-MEL-2) [6]
Vandetanib + Cisplatin DC9TM3S Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Vandetanib + Cisplatin DCKAF8B Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vemurafenib + Cisplatin DCW0AHL Vemurafenib Carcinoma (Cell Line: MCF7) [5]
Vemurafenib + Cisplatin DCO25DO Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vemurafenib + Cisplatin DCCPS8A Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Vemurafenib + Cisplatin DC2AL07 Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vemurafenib + Cisplatin DCV5I59 Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vemurafenib + Cisplatin DCDW36K Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Vemurafenib + Cisplatin DC8YIVU Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [6]
Vincristine + Cisplatin DCCRXR3 Vincristine Adenocarcinoma (Cell Line: HCT-15) [4]
Vincristine + Cisplatin DCKVWOK Vincristine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vincristine + Cisplatin DCC4PY0 Vincristine Glioma (Cell Line: SF-295) [4]
Vinflunine + Cisplatin DCOF3ZI Vinflunine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vinflunine + Cisplatin DCF2FF2 Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vinflunine + Cisplatin DCA1FK7 Vinflunine Astrocytoma (Cell Line: U251) [4]
Vinflunine + Cisplatin DCV4A4A Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vinflunine + Cisplatin DC9MEPD Vinflunine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Vinflunine + Cisplatin DCR7APJ Vinflunine Adenocarcinoma (Cell Line: HCT116) [6]
Vinflunine + Cisplatin DCIXPBU Vinflunine Malignant melanoma (Cell Line: LOX IMVI) [6]
Vinflunine + Cisplatin DCFFWL4 Vinflunine Malignant melanoma (Cell Line: UACC62) [6]
Vismodegib + Cisplatin DCQYW3C Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vismodegib + Cisplatin DC41FDE Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vismodegib + Cisplatin DCHXMKM Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vismodegib + Cisplatin DCONA4R Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [6]
Vismodegib + Cisplatin DCXQDRJ Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Vismodegib + Cisplatin DCWE0V2 Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vismodegib + Cisplatin DC43KDC Vismodegib Renal cell carcinoma (Cell Line: UO-31) [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 398 DrugCom(s)
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Cisplatin + Thymalfasin DCJ3HN3 Thymalfasin Hepatitis virus infection [7]
------------------------------------------------------------------------------------

References

1 Cisplatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5343).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
7 Clinical pipeline report, company report or official report of SciClone Pharmaceuticals.